



BARCELONA SPAIN

20-21 OCTOBER 2017

Co-Chairs Claus-Henning Köhne, DE

Michel Ducreux, FR

ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care and future perspectives

Barcelona, Spain 20-21 October 2017

CO-CHAIRS: Claus-Henning Köhne, Germany

Michel Ducreux, France

SPEAKERS: Frédéric Bibeau, France

Robert Glynne-Jones, United Kingdom

Stefan Heinrich, Germany Pierre Laurent-Puig, France Pompiliu Piso, Germany Ramon Salazar, Spain

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the options in the continuum of care, management treatment side-effects and in the challenges of special clinical situations

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland

Email: courses@esmo.org

www.esmo.org



09:00-09:15 15'	Welcome and introduction	Claus-Henning Köhne, DE
09:15-10:50 95'	SESSION 1 Early colorectal cancer	Chair: Claus-Henning Köhne, DE
30'	The pathologist's view - The pathology report - Histo-prognostic factors: No LN, lymphocytic invasion MSH, expression	Frédéric Bibeau, FR
20'	State-of-the-art of surgery for resectable primary tumours (special focus on rectal cancer)	Stefan Heinrich, DE
25'	State-of-the-art: Radio-/chemotherapy for rectal cancer	Robert Glynne-Jones, UK
20'	The role of postoperative chemotherapy in rectal cancer	Michel Ducreux, FR
10:50-11:20	Coffee break	
11:20-12:50 90'	SESSION 2 Adjuvant treatment of colorectal cancer	Chair: Michel Ducreux, FR
30'	Microsatellite instability and other molecular markers	Frédéric Bibeau, FR
30'	Adjuvant treatment for stage II and III colon cancer	Ramon Salazar, ES
3x10'	3 x Participant clinical case discussion	Faculty
12:50-14:00	Lunch	
14:00-15:30 90'	SESSION 3 Metastatic colorectal cancer: Liver limited or oligometastatic CRC	Chair: Ramon Salazar, ES
30'	Review of the ESMO consensus conference on metastatic CRC - Basis strategies and groups (RAS, BRAF, etc)	Michel Ducreux, FR
30'	Treating liver limited or oligometastatic CRC	Claus-Henning Köhne, DE
3x10'	3 x Participant clinical case discussion	Faculty
15:30-16:00	Coffee break	
16:00-17:10 70'	SESSION 4 Metastatic colorectal cancer: Special clinical situations	Chair: Michel Ducreux, FR
00'	How to treat peritoneal dominant disease (resection, PIPEC, HIPEC)	Pompiliu Piso, DE
20'		
20'	Primary tumour with synchronous metastases	Stefan Heinrich, DE
	Primary tumour with synchronous metastases Interventional radiology and/or stereotactic radiotherapy	Stefan Heinrich, DE Robert Glynne-Jones, UK
20'		<u> </u>
20' 10' 20' 17:10-17:40	Interventional radiology and/or stereotactic radiotherapy Locoregional therapy for liver metastases SESSION 5	Robert Glynne-Jones, UK Michel Ducreux, FR Chair:
20' 10' 20'	Interventional radiology and/or stereotactic radiotherapy Locoregional therapy for liver metastases	Robert Glynne-Jones, UK Michel Ducreux, FR

Saturday, 21 October 2017

08:30-12:00 180'	SESSION 5 - Part II Metastatic colorectal cancer: Continuum of care	Chair: Claus-Henning Köhne, DE	
30'	SPECIAL LECTURE The role of liquid biopsies and circulating tumor DNA	Pierre Laurent-Puig, FR	
30,	The role of maintenance	Michel Ducreux, FR	
30'	What is best for 2 nd line?	Ramon Salazar, ES	
30'	Later lines of treatment (Regorafenib, TAS 102, reintroduction) and the concept of continuum of care	Claus-Henning Köhne, DE	
10:30-11:00	Coffee break		
30'	Management of side effects	Michel Ducreux, FR	
3x10'	3 x Participant clinical case discussion	Faculty	
12:00-12:45 45'	SESSION 6 Anal canal tumours	Chairs: Michel Ducreux, FR Claus-Henning Köhne, DE	
30'	Standard of care for anal tumours	Robert Glynne-Jones, UK	
15'	Salvage surgery of anal canal tumours	Pompiliu Piso, DE	
12:45-13:00 15'	Conclusion and farewell	Chair: Claus-Henning Köhne, DE	
13:00-14:00	Lunch		

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion